The practice of medicine has long been shifting from the classical model of clinical care based on signs and symptoms to the application of biomarker guided decision making.
In a clinical setting, biomarkers can be classified as follows:
- Preventative – identifying outwardly healthy people at a high risk of developing disease
- Diagnostic – identify a disease at the earliest stage, before clinical symptoms occur
- Prognostic – stratify the risk of disease progression in patients undergoing specific therapy
- Predictive – identify patients who respond to specific therapeutic interventions
- Therapeutic –provide a quantifiable measure of response in patients who undergo treatment
Affinity Biomarker Labs mission is to assist principal investigators and clinicians discover, validate and translate potentially lifesaving biomarkers in a robust, cost effective and timely manner.
Through a close working relationship with leading academics and teaching hospitals including King’s College Hospital, Imperial College, Guy’s and St Thomas’ and Newcastle University to name a few, Affinity Biomarker Labs is the ideal partner to support your clinical biomarker development program.